Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.84 |
| ▸ | ERBB4 | Q15303 | 5/20 | 0.84 |
| ▸ | JAK3 | P52333 | 2/20 | 0.84 |
| ▸ | SRC | P12931 | 3/20 | 0.77 |
| ▸ | ABL1 | P00519 | 2/20 | 0.77 |
| ▸ | FLT3 | P36888 | 2/20 | 0.77 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.77 |
| ▸ | GAK | O14976 | 2/20 | 0.77 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.77 |
| ▸ | LCK | P06239 | 2/20 | 0.77 |
| ▸ | MC3R | P41968 | 2/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | CIT | O14578 | 1/20 | 0.77 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.77 |
| ▸ | STK10 | O94804 | 1/20 | 0.77 |
| ▸ | LYN | P07948 | 1/20 | 0.77 |
| ▸ | RET | P07949 | 1/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867638 | 1.00 | EGFR (0.85) | EGFRERBB2ERBB4JAK3SRC | |
| SCHEMBL20325402 | 0.94 | EGFR (0.83) | EGFRERBB2ERBB4JAK3SRC | |
| SCHEMBL19639014 | 0.93 | EGFR (0.87) | EGFRERBB2ERBB4JAK3SRC | |
| SCHEMBL30101593 | 0.93 | EGFR (0.87) | EGFRERBB2ERBB4JAK3SRC | |
| SCHEMBL17538522 | 0.92 | EGFR (1.00) | EGFRERBB2ERBB4JAK3SRC | |
| Mifanertinib SCHEMBL30071723 | 0.91 | EGFR (0.82) | EGFRERBB2ERBB4JAK3SRC | |
| Mifanertinib SCHEMBL28654412 | 0.91 | EGFR (0.82) | EGFRERBB2ERBB4JAK3SRC | |
| Mifanertinib SCHEMBL21620274 | 0.91 | EGFR (0.82) | EGFRERBB2ERBB4JAK3SRC | |
| Mifanertinib SCHEMBL16547603 | 0.91 | EGFR (0.82) | EGFRERBB2ERBB4JAK3SRC | |
| SCHEMBL10108265 | 0.91 | EGFR (0.72) | EGFRERBB2ERBB4JAK3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | disclosed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 48/4885ERBB2 7/4885ERBB4 17/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 41/4885ERBB2 7/4885ERBB4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.